Clinafloxacin antibacterial activity

Drugs

Volumn 58, Issue SUPPL. 2, 1999, Pages 217-221

  Ednie, Lois M ^a   Jacobs, Michael R ^b   Appelbaum, Peter C ^a  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFTAZIDIME; CIPROFLOXACIN; CLINAFLOXACIN; COTRIMOXAZOLE; IMIPENEM; LEVOFLOXACIN; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; SPARFLOXACIN; TROVAFLOXACIN;

ACINETOBACTER; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; BURKHOLDERIA CEPACIA; CHRYSEOBACTERIUM; CITROBACTER; CONFERENCE PAPER; ENTEROBACTER; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; ESCHERICHIA COLI; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; KLEBSIELLA; MINIMUM INHIBITORY CONCENTRATION; MORGANELLA; NONHUMAN; PSEUDOMONAS AERUGINOSA; SERRATIA; STAPHYLOCOCCUS; STENOTROPHOMONAS MALTOPHILIA; STREPTOCOCCUS PNEUMONIAE;

ACINETOBACTER; BACTERIA (MICROORGANISMS); BURKHOLDERIA; BURKHOLDERIA CEPACIA; CHRYSEOBACTERIUM; CITROBACTER; ENTEROBACTER; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; ESCHERICHIA COLI; KLEBSIELLA; NEGIBACTERIA; POSIBACTERIA; PSEUDOMONAS; PSEUDOMONAS AERUGINOSA; SERRATIA; STAPHYLOCOCCUS; STENOTROPHOMONAS MALTOPHILIA; STREPTOCOCCUS PNEUMONIAE;

EID: 0032755480     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199958002-00066     Document Type: Conference Paper

References (10)

1. Bron NJ, Dorr MB, Mant TG, et al. The tolerance and pharmacokinetics of clinafloxacin (CI-960) in healthy subjects. J Antimicrob Chemother 1996; 38: 1023-9
2. Cohen MA, Huband MD, Gage JW, et al. In-vitro activity of clinafloxacin, trovafloxacin, and ciprofloxacin. J Antimicrob Chemother 1997; 40: 205-11
3. Cohen MA, Huband MD, Mailloux GB, et al. In vitro antibacterial activities of the fluoroquinolones PD 117596, PD 124816, and PD 127391. Diagn Microbiol Infect Dis 1991; 14: 245-8
4. Cohen MA, Yoder SL, Huband MD, et al. In vitro and in vivo activities of clinafloxacin, CI-990 (PD 131112), and PD 138312 versus enterococci. Antimicrob Agents Chemother 1995; 39: 2123-7
5. Cormican, MG, Jones RN. Cross-resistance analysis for clinafloxacin compared with ciprofloxacin, fleroxacin, ofloxacin, and sparfloxacin using a predictor panel of ciprofloxacin-resistant bacteria. J Antimicrob Chemother 1995; 36: 431-4
6. Fuchs PC, Barry AL, Pfaller MA, et al. Multicenter evaluation of the in vitro activities of three new quinolones, sparfloxacin, CI-960, and PD 131,628, compared with the activity of ciprofloxacin against 5,252 clinical bacterial isolates. Antimicrob Agents Chemother 1991; 35: 764-6
7. Harrington GD, Zarins LT, Ramsey MA, et al. Susceptibility of ciprofloxacin-resistant staphylococci and enterococci to clinafloxacin. Diagn Microbiol Infect Dis 1995; 21: 27-31
8. Itokazu GS, Nathan C, Hariharan R, et al. The comparative in vitro activity of clinafloxacin and other antimicrobials against vancomycin-susceptible and vancomycin-resistant enterococci. Chemotherapy 1996; 42: 235-9
9. King A, Boothman C, Phillips I. The in-vitro activity of PD127,391, a new quinolone. J Antimicrob Chemother 1988; 22: 135-41
10. Norrby SR, Jonsson M. Comparative in-vitro activity of PD 127,391, a new fluorinated 4-quinolone derivative. Antimicrob Agents Chemother 1988; 32: 1278-81